Outcomes in COVID-19 conestat alfa studies

All studies   Mortality   Ventilation   ICU   Hospitalization   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -14% 2 121 Improvement, Studies, Patients Relative Risk Mortality -14% 2 121 Ventilation 17% 2 121 ICU admission -141% 1 83 Hospitalization 52% 1 38 RCTs -14% 2 121 RCT mortality -14% 2 121 Peer-reviewed -238% 1 83 Late -14% 2 121 Conestat alfa for COVID-19 c19early.org December 2025 Favorsconestat alfa Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] death 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 studies c19early.org December 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Effect extraction pre-specified(most serious outcome) Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 mortality results c19early.org December 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 87% 0.13 [0.01-2.44] 0/27 2/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -286% 3.86 [0.51-29.3] 8/56 1/27 Tau​2​ = 4.17, I​2​ = 71.3%, p = 0.92 Late treatment 17% 0.83 [0.03-23.3] 8/83 3/38 17% lower risk All studies 17% 0.83 [0.03-23.3] 8/83 3/38 17% lower risk 2 conestat alfa COVID-19 mechanical ventilation results c19early.org December 2025 Tau​2​ = 4.17, I​2​ = 71.3%, p = 0.92 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PROTECT-COVID-19 Urwyler (RCT) -141% 2.41 [0.57-10.2] 10/56 2/27 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -141% 2.41 [0.57-10.2] 10/56 2/27 141% higher risk All studies -141% 2.41 [0.57-10.2] 10/56 2/27 141% higher risk 1 conestat alfa COVID-19 ICU result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 52% 0.48 [0.22-1.04] hosp. time 27 (n) 11 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.063 Late treatment 52% 0.48 [0.22-1.04] 27 (n) 11 (n) 52% lower risk All studies 52% 0.48 [0.22-1.04] 27 (n) 11 (n) 52% lower risk 1 conestat alfa COVID-19 hospitalization result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.063 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] death 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 serious outcomes c19early.org December 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Effect extraction pre-specified(most serious outcome) Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PROTECT-COVID-19 Urwyler (RCT) -117% 2.17 [0.81-5.79] no disch. 18/56 4/27 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.12 Late treatment -117% 2.17 [0.81-5.79] 18/56 4/27 117% higher risk All studies -117% 2.17 [0.81-5.79] 18/56 4/27 117% higher risk 1 conestat alfa COVID-19 recovery result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.12 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] death 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 Randomized Controlled Trials c19early.org December 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Effect extraction pre-specified(most serious outcome) Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 RCT mortality results c19early.org December 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.25 Late treatment -238% 3.38 [0.44-26.1] 7/56 1/27 238% higher risk All studies -238% 3.38 [0.44-26.1] 7/56 1/27 238% higher risk 1 conestat alfa COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.25 Effect extraction pre-specified(most serious outcome) Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] death 0/27 1/11 Improvement, RR [CI] Treatment Control Bernstein (SB RCT) 87% 0.13 [0.01-2.44] ventilation 0/27 2/11 Bernstein (SB RCT) 46% 0.54 [0.28-1.05] progression 12/27 9/11 Bernstein (SB RCT) 52% 0.48 [0.22-1.04] hosp. time 27 (n) 11 (n) PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 PROTECT-COVID-19 Urwyler (RCT) -889% 9.89 [0.58-169] death 6/56 0/27 PROTECT-COVID-19 Urwyler (RCT) -296% 3.96 [0.20-79.8] death 2/56 0/27 PROTECT-COVID-19 Urwyler (RCT) -286% 3.86 [0.51-29.3] ventilation 8/56 1/27 PROTECT-COVID-19 Urwyler (RCT) -141% 2.41 [0.57-10.2] ICU 10/56 2/27 PROTECT-COVID-19 Urwyler (RCT) -117% 2.17 [0.81-5.79] no disch. 18/56 4/27 Conestat alfa COVID-19 outcomes c19early.org December 2025 Favors conestat alfa Favors control